Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, Phipps C, Lee YS, Grigoropoulos NF, Lao Z, Surendran S, Teh EM, Goh YT, Chng WJ, Gopalakrishnan SK. Chen Y, et al. Among authors: goh yt. Blood Cancer J. 2016 Jul 29;6(7):e450. doi: 10.1038/bcj.2016.62. Blood Cancer J. 2016. PMID: 27471866 Free PMC article. No abstract available.
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, Ong SY, Xu M; SGHMM1 Investigators; Chng WJ, Goh YT, Nagarajan C. Chen Y, et al. Among authors: goh yt. Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x. Blood Cancer J. 2021. PMID: 34480015 Free PMC article. Clinical Trial. No abstract available.
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Among authors: goh yt. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH. Tan D, et al. Among authors: goh yt. Leuk Res. 2013 Sep;37(9):1070-6. doi: 10.1016/j.leukres.2013.06.008. Epub 2013 Jun 28. Leuk Res. 2013. PMID: 23816344
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.
Tay T, Somasundaram N, Lim C, Khoo LP, Goh AZK, Lee YS, Liu X, Tao M, Quek R, Farid M, Poon E, Chan JYS, Chang EWY, Yang VSW, Goh YT, Tan D, Diong C, Grigoropoulos NF, Nagarajan C, Poon M, de Mel S, Jeyasekharan A, Chan EHL, Lee J, Chee YL, Lim ST, Tang T. Tay T, et al. Among authors: goh yt, goh azk. Cancer Rep (Hoboken). 2022 Sep;5(9):e1552. doi: 10.1002/cnr2.1552. Epub 2022 Apr 28. Cancer Rep (Hoboken). 2022. PMID: 35481622 Free PMC article.
The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, Tang T, Goh AZ, Ghosh A, Ng HJ, Gopalakrishnan S, Loh Y, Lim ST, Hwang W, Tan D, Goh YT. Phipps C, et al. Among authors: goh yt, goh az. Leuk Lymphoma. 2018 Oct;59(10):2336-2341. doi: 10.1080/10428194.2017.1422863. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345210
150 results